Anoplin [G1Beta-Ala]

General Information


DRACP ID  DRACP01000

Peptide Name   Anoplin [G1Beta-Ala]

Sequence  XLLKRIKTLL

Sequence Length  10

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma 20% Killing=256 µM MTT assay 24h 1

Hemolytic Activity  Horse erythrocytes : <5% Hemolysis=256µM

Normal (non-cancerous) Cytotoxicity  HEK293T: 15% Hemolysis=256µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  X(1)=Beta-Ala

Chiral  L



Physicochemical Information


Formula  C52H98N14O10

Absent amino acids  ACDEFGHMNPQSVWY

Common amino acids  L

Mass  135016

Pl  11.82

Basic residues  3

Acidic residues  0

Hydrophobic residues  5

Net charge  3

Boman Index  -399

Hydrophobicity  67

Aliphatic Index  195

Half Life 
  /

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  1

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 32654770

Title  Synthesis and anti-pseudomonal activity of new ß-Ala modified analogues of the antimicrobial peptide anoplin

Doi 10.1016/j.ijmm.2020.151433

Year  2020

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.